MedTrace Logo

Exercise Booster Sessions in People With Multiple Sclerosis

NCT04913012 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-12-27

No results posted yet for this study

Summary

This study wants to investigate whether exercise booster sessions applied in the follow-up period after an exercise intervention can increase the sustainability of exercise induced effects in persons with multiple sclerosis.

The study will be a randomized, multi-site, controlled trial. Participants will from the beginning be allocated to either aerobic training group, resistance training group or control group. After a 12 week exercise intervention, the exercise groups will be additionally randomized to receive either exercise booster sessions + standard care or just standard care in the 40 week follow up period.

It is hypothesized that exercise booster sessions can increase the sustainability of exercise induced effects.

Conditions

Interventions

COMBINATION_PRODUCT

Systematic aerobic training

Two-three weekly supervised aerobic exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

COMBINATION_PRODUCT

Systematic resistance training

Two-three weekly supervised resistance exercise sessions for 12 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.

COMBINATION_PRODUCT

Aerobic training booster sessions

Supervised aerobic training booster sessions delivered in the follow up period (two sessions every fifth week).

COMBINATION_PRODUCT

Resistance training booster sessions

Supervised resistance training booster sessions in the follow up period (two sessions every fifth week).

Sponsors & Collaborators

  • Oxford Brookes University

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Laurits Taul-Madsen, MSc. · University of Aarhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2024-10-04
Completion
2024-10-04

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913012 on ClinicalTrials.gov